PMID- 30074150
OWN - NLM
STAT- MEDLINE
DCOM- 20181029
LR  - 20200624
IS  - 2523-899X (Electronic)
IS  - 2523-899X (Linking)
VI  - 38
IP  - 1
DP  - 2018 Feb
TI  - Subcutaneous versus Intravenous Bortezomib Administration for Multiple Myeloma 
      Patients: a Meta-analysis.
PG  - 43-50
LID - 10.1007/s11596-018-1844-y [doi]
AB  - Bortezomib, the first potent therapeutic proteasome inhibitor, has been suggested 
      as a standard care in patients with newly diagnosed and relapsed multiple myeloma 
      (MM). However, evidence bearing on the efficacy and safety of subcutaneous (SC) 
      versus intravenous (IV) administration of bortezomib for MM patients is 
      controversial. Randomised controlled trials (RCTs) and observational studies were 
      enrolled in our meta-analysis to investigate the efficacy and safety of 
      bortezomib via SC vs. IV administration on MM patients. Sixteen trials with a 
      total of2575 patients with MM (SC, n=1191; IV, n=1384) were included in our 
      meta-analysis. There were no significant differences between these two arms 
      regarding overall response rate (ORR), complete response (CR), or very good 
      partial response (VGPR). The pooled RRs for rate of adverse events (AEs), such as 
      thrombocytopenia and bortezomib-induced peripheral neuropathy (BIPN), were 0.79 
      (95% CI: 0.68-0.92) and 0.63 (95% CI: 0.51-0.79), respectively. Moreover, there 
      was much more largely decreased incidence of grade 3 and higher thrombocytopenia 
      and BIPN in bortezomib SC administration than IV route. In general, alternative 
      SC administration should be considered instead of IV administration in use of 
      bortezomib for patients with MM. Key words: bortezomib; multiple myeloma; 
      meta-analysis; subcutaneous administration.
FAU - Mu, Shi-Dai
AU  - Mu SD
AD  - Institute of Hematology, Huazhong University of Science and Technology, Wuhan, 
      430022, China.
FAU - Ai, Li-Sha
AU  - Ai LS
AD  - Institute of Hematology, Huazhong University of Science and Technology, Wuhan, 
      430022, China.
FAU - Qin, You
AU  - Qin Y
AD  - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of 
      Science and Technology, Wuhan, 430022, China.
FAU - Hu, Yu
AU  - Hu Y
AD  - Institute of Hematology, Huazhong University of Science and Technology, Wuhan, 
      430022, China. dr_huyu@126.com.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20180315
PL  - China
TA  - Curr Med Sci
JT  - Current medical science
JID - 101729993
RN  - 0 (Antineoplastic Agents)
RN  - 69G8BD63PP (Bortezomib)
SB  - IM
MH  - Administration, Intravenous/*adverse effects
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/*administration & dosage/therapeutic use
MH  - Bortezomib/*administration & dosage/adverse effects/therapeutic use
MH  - Female
MH  - Humans
MH  - Injections, Subcutaneous/*adverse effects
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/*drug therapy
MH  - Observational Studies as Topic
MH  - Peripheral Nervous System Diseases/etiology
MH  - Randomized Controlled Trials as Topic
MH  - Thrombocytopenia/etiology
OTO - NOTNLM
OT  - bortezomib
OT  - meta-analysis
OT  - multiple myeloma
OT  - subcutaneous administration
EDAT- 2018/08/04 06:00
MHDA- 2018/08/04 06:01
CRDT- 2018/08/04 06:00
PHST- 2017/06/20 00:00 [received]
PHST- 2018/01/10 00:00 [revised]
PHST- 2018/08/04 06:00 [entrez]
PHST- 2018/08/04 06:00 [pubmed]
PHST- 2018/08/04 06:01 [medline]
AID - 10.1007/s11596-018-1844-y [pii]
AID - 10.1007/s11596-018-1844-y [doi]
PST - ppublish
SO  - Curr Med Sci. 2018 Feb;38(1):43-50. doi: 10.1007/s11596-018-1844-y. Epub 2018 Mar 
      15.